IC
SRPT icon

Ikarian Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ikarian Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-137,000
Closed -$2.64M – 219
2025
Q3 		$2.64M Sell
137,000
-195,100
-59% -$3.48M 0.27% 88
2025
Q2 		$5.68M Buy
+332,100
New +$14.2M 1.09% 31
2025
Q1 		– Sell
-81,000
Closed -$9.85M – 213
2024
Q4 		$9.85M Buy
+81,000
New +$9.93M 1.34% 14
2024
Q3 		– Sell
-1,000
Closed -$15.8M – 169
2024
Q2 		$15.8M Sell
1,000
-115,100
-99% -$14.8M 2.75% 10
2024
Q1 		$15M Sell
116,100
-66,500
-36% -$8.15M 1.65% 17
2023
Q4 		$17.6M Buy
182,600
+180,477
+8,501% +$17.3M 1.65% 20
2023
Q3 		$25.7M Sell
2,123
-19,977
-90% -$2.26M 3.1% 7
2023
Q2 		$2.53M Sell
22,100
-183,300
-89% -$23.6M 0.4% 57
2023
Q1 		$28.3M Buy
+205,400
New +$26.6M 6.42% 2
2022
Q4 		– Sell
-85,200
Closed -$9.42M – 106
2022
Q3 		$9.42M Sell
85,200
-14,800
-15% -$1.49M 1.88% 16
2022
Q2 		$7.5M Buy
+100,000
New +$7.36M 1.37% 26
2022
Q1 		– Sell
-399,400
Closed -$36M – 211
2021
Q4 		$36M Buy
399,400
+37,700
+10% +$3.22M 5.36% 3
2021
Q3 		$33.4M Buy
361,700
+311,700
+623% +$24M 2.36% 10
2021
Q2 		$3.89M Sell
50,000
-50,000
-50% -$3.79M 0.31% 78
2021
Q1 		$7.45M Sell
100,000
-401,000
-80% -$37M 0.25% 88
2020
Q4 		$85.4M Buy
501,000
+398,400
+388% +$59M 3.77% 7
2020
Q3 		$14.4M Buy
102,600
+100,000
+3,846% +$15.2M 1.04% 23
2020
Q2 		$417K Sell
2,600
-100,000
-97% -$13.6M 0.03% 137
2020
Q1 		$10M Hold
102,600
– – 0.75% 35
2019
Q4 		$13.2M Buy
+102,600
New +$10.4M 2.15% 7

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ikarian Capital's SRPT Position: Q3 2025 in Review

Ikarian Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 449,087 shares — an estimated $8.01M sold.

Ikarian Capital first reported a position in SRPT in Q1 2021 and held it in 13 quarters. The position peaked at $32.2M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Ikarian Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 449,087 Sarepta Therapeutics shares in Q3 2025, an estimated $8.01M.
  • Ikarian Capital first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 13 quarters.
  • Ikarian Capital's Sarepta Therapeutics position peaked at $32.2M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.